Watch the replay of the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients&Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.
Monoclonal antibodies are an exciting theapeutic avenue for hematological cancers, including multiple myeloma (MM). Here, Neils van de Donk, MD, PhD, of VU University Medical Centre, Amsterdam, Nether... Author: VJHemOnc Added: 07/20/2018
Publication date: August 2018Source: Cancer Epidemiology, Volume 55Author(s): Chao-Hsiun Tang, Hung-Yi Liu, Hsin-An Hou, Hong Qiu, Kuan-Chih Huang, Sarah Siggins, Lee Anne Rothwell, Yanfang LiuAbstractBackgroundAlthough the incidence of multiple myeloma (MM) in Asia is lower than in Western countries, it is steadily increasing. However, limited data are available that describe the epidemiology of MM in Asia.MethodsWe conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database to estimate the disease burden and clinical characteristics of patients with MM in Taiwan. All newly diag...
AbstractThe construction of a tumor-associated carbohydrate antigen-zwitterionic polysaccharide conjugate, Thomsen-nouveau-polysaccharide A1 (Tn-PS A1, where Tn = d-GalpNAc), has led to the development of a carbohydrate binding monoclonal antibody named Kt-IgM-8. Kt-IgM-8 was produced via hybridoma from Tn-PS A1 hyperimmunized Jackson Laboratory C57BL/6 mice, splenocytes and the murine myeloma cell line Sp2/0Ag14 with subsequent cloning on methyl cellulose semi-solid media. This in-house generated monoclonal antibody negates binding influenced from peptides, proteins, and lipids and preferentially binds mono...
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) developing in persons exposed to DNA-damaging agents for a prior cancer are often referred to as treatment- or therapy-related myeloid neoplasms (t-MN)[1,2]. t-MN constitute approximately 10-20% of all cases of AML and MDS, a proportion that may increase in the future with an increasing prevalence of cancer survivors[4,5]. Hematopoietic cell transplants (HCT) use high doses of drugs and/or ionizing radiations and can also lead to t-MN[6,7].
Conclusions: HIF-2 α expression may be associated with the carcinogenesis of CRC, which is higher in males than in females, negatively linked to tumor differentiation, and correlated with a worse DFS of CRC. Additional prospective studies are needed.Cell Physiol Biochem 2018;48:516 –527
This study identified a previously unrecognized regulatory axis between AHR and polyamine metabolism and discovered clofazimine as an inhibitor of AHR and a potentially clinically-relevant anti-multiple myeloma agent.RNA-seq: human multiple myeloma MM1S and human normal fibroblasts WI38 cells -/+ CLF 2-4uM for 24hrs; -/+ shAHR
CAR T-cell therapy has proven to be a highly effective, breakthrough therapy for treating acute lymphoblastic leukemia and acute myeloid leukemia. Here, Nikhil Munshi, MD, from the Dana-Farber Cancer ... Author: VJHemOnc Added: 07/16/2018
CONCLUSIONS: In conclusion, the results indicate that carvone could prove to be an important molecule for the development of natural product-based anticancer therapy, especially against myeloma. PMID: 30003746 [PubMed - in process]
The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions. It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma. In neuroblastoma, patients undergo a very aggress ive standard of care regimen that results in a high mortality rate. Many neuroblastomas have increased expression of CD56, which represents a possible therapeutic target for these...